It wasn't a considered response, it was 5mins of googling the Genocury announcement. If you're expecting comprehensive discussion maybe consider providing higher quality contributions and refrain from misrepresenting anything and everything you can get your hands on to sink the boot in.
Yes IMU need funds, it's highly likely but not a foregone conclusion holders will be heavily diluted. I think IMU not being able to achieve their clinical objectives, and unlock potential value in the current pipeline, is a significantly worse proposition for existing holders than a dilutionary event. Anyway, is this somehow relevant to your assessment of IMU's competition?
IMU Price at posting:
2.4¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)